SEC Form 4 · accession 0001144204-15-021235
INTERCEPT PHARMACEUTICALS, INC. · ICPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Luciano Adorini
Officer — Chief Scientific Officer
Period of report
Apr 1, 2015
Accepted (ET)
Apr 3, 2015 · 9:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001270073
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F1 | Apr 1, 2015 | M | 649 | — | A | 10,060 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF1,F2 | — | Apr 1, 2015 | M | 649 | D | — | — | Common Stock | 649 | 1,947 | D |
Explanation of responses
- F1Conversion of restricted stock units ("RSUs") to shares of common stock on a one-to-one basis.
- F2On November 16, 2012, the reporting person was granted 10,384 RSUs. The RSUs reported as having been disposed and the corresponding shares reported as having been acquired, representing 6.25% of the shares underlying the RSUs, became vested on April 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remainder of the shares underlying the RSUs will vest pro rata on a quarterly basis from July 1, 2015 through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.